Zobrazeno 1 - 10
of 99
pro vyhledávání: ''
Autor:
Su Young Kim, Ruby Nandam, Brenda Chyla, Shuo Ma, John Pesko, John F. Seymour, Ahmed Salem, Amanda Jacobson, Michael Y. Choi, Thomas J. Kipps, Andrew W. Roberts, Abdullah A. Masud, Mary Ann Anderson, Jennifer Arzt, Danielle M. Brander, Kathryn Humphrey
Publikováno v:
Blood
We report long-term follow-up of the phase 1b study of venetoclax and rituximab (VenR) in patients with relapsed chronic lymphocytic leukemia (CLL), including outcomes with continuous or limited-duration therapy. Patients received venetoclax daily (2
Autor:
Michel Attal, Xavier Leleu, Salomon Manier, Lotfi Benboubker, Clara Mariette, Cécile Sonntag, Karim Belhadj, Denis Caillot, Cyrille Touzeau, Martine Escoffre-Barbe, Benjamin Hebraud, Laurent Garderet, Soraya Wuilleme, Philippe Moreau, Jill Corre, Valérie Lauwers-Cances, Thierry Facon, Jehan Dupuis, Murielle Roussel
Publikováno v:
Blood. 138:113-121
Bortezomib, lenalidomide, and dexamethasone plus transplant is a standard of care for eligible patients with multiple myeloma. Because responses can deepen with time, regimens with longer and more potent induction/consolidation phases are needed. In
Autor:
Johan Maertens, Annoek E.C. Broers, Yvette van Norden, Mojca Jongen-Lavrencic, Gert J. Ossenkoppele, Michel van Gelder, Jan J. Cornelissen, Wendelien Zeijlemaker, Burak Kalin, Ellen Meijer, Dimitri Breems, Eric Braakman, Tim Grob
Publikováno v:
BLOOD ADVANCES, 4(18), 4430-4437. American Society of Hematology
Blood advances, 4(18), 4430-4437. American Society of Hematology
Kalin, B, van Norden, Y, van Gelder, M, Breems, D, Maertens, J, Jongen-Lavrencic, M, Broers, A E C, Braakman, E, Grob, T, Zeijlemaker, W, Ossenkoppele, G J, Meijer, E & Cornelissen, J J 2020, ' Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation ', BLOOD ADVANCES, vol. 4, no. 18, pp. 4430-4437 . https://doi.org/10.1182/BLOODADVANCES.2020002074
Blood Adv
Blood advances, 4(18), 4430-4437. The American Society of Hematology
Blood advances, 4(18), 4430-4437. American Society of Hematology
Kalin, B, van Norden, Y, van Gelder, M, Breems, D, Maertens, J, Jongen-Lavrencic, M, Broers, A E C, Braakman, E, Grob, T, Zeijlemaker, W, Ossenkoppele, G J, Meijer, E & Cornelissen, J J 2020, ' Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation ', BLOOD ADVANCES, vol. 4, no. 18, pp. 4430-4437 . https://doi.org/10.1182/BLOODADVANCES.2020002074
Blood Adv
Blood advances, 4(18), 4430-4437. The American Society of Hematology
Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early initiation of e
Autor:
Bianca Rocca, Francesca Palandri, Giovanna Petrucci, Chiara Paoli, Cristina Bucelli, Benedetta Porro, Nicola Vianelli, Francesco Rodeghiero, Elena Rossi, Alessandra Iurlo, Carlo Patrono, Irene Bertozzi, Alessandro M. Vannucchi, Maria Luigia Randi, Andrea Timillero, Monica Carpenedo, Mauro Di Ianni, Giuseppe Carli, Alfredo Dragani, Silvia Betti, Denise Soldati, Elena Maria Elli, Eloise Beggiato, Valerio De Stefano, Daniele Cattaneo, Giuseppe Lanzarone, Alberto Tosetto, Viviana Cavalca, Marco Ruggeri, Giorgina Specchia, Alessandra Ricco, Paola Ranalli
Publikováno v:
Blood. 136:171-182
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet
Autor:
Christoffer Flensburg, Piers Blombery, David C.S. Huang, Huaxian Ma, Giovanna Pomilio, Sarah MacRaild, Sanam Loghavi, Rachel Thijssen, Fiona C. Brown, Ian J. Majewski, Jessica M. Salmon, Ing Soo Tiong, Hagop M. Kantarjian, Adam Ivey, Xufeng Chen, Keyur P. Patel, Ioannis Aifantis, A. Quaglieri, Shaun Fleming, Courtney D. DiNardo, Zhen Xu, Andrew W. Roberts, Marina Konopleva, Nik Cummings, Qi Zhang, Andrew H. Wei, Steve Kornblau, Chong Chyn Chua, Christina Glytsou
Publikováno v:
Blood. 135:791-803
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based com
Autor:
Sanjeet Dadwal, Jianying Zhang, David S. Snyder, Matthew Mei, Stephen J. Forman, Haris Ali, Karamjeet S. Sandhu, Bernard Tegtmeier, Ahmed Aribi, Vinod Pullarkat, Samer K. Khaled, Amandeep Salhotra, Monzr M. Al Malki, Shukaib Arslan, Ibrahim Aldoss, Anthony S. Stein, Guido Marcucci, Ryotaro Nakamura
Publikováno v:
Blood Advances. 3:4043-4049
The combination of venetoclax with hypomethylating agents (VEN-HMAs) showed promising activity in newly diagnosed and relapsed/refractory (r/r) acute myeloid leukemia (AML). Treatment with VEN-HMAs results in prolonged cytopenia, thereby exposing pat
Autor:
Elisabet E. Manasanch, Surbhi Sidana
Publikováno v:
Hematology Am Soc Hematol Educ Program
You are evaluating a 47-year-old man with revised international staging system stage III myeloma who recently underwent an autologous stem cell transplant after receiving 6 cycles of carfilzomib, lenalidomide, and dexamethasone for newly diagnosed di
Autor:
Brett M. Stevens, Mark D. Ewalt, Diana Abbott, Daniel A. Pollyea, Stephanie Chase, Jennifer Tobin, Molly Nakic, Chelsey Boggs, Jeffrey Schowinsky, Bradford Siegele, Steven R. Schuster, Jonathan A. Gutman, Keri Halsema, Enkhtsetseg Purev, Lindsey Lyle, Jeff Kaiser, Clayton A. Smith, Amanda Winters, Julie Rosser, Craig T. Jordan, Vishal Rana
Publikováno v:
Blood Advances. 3:2911-2919
Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients. Venetoclax was available prior to approval off-label. We assessed our single-institution off-label experience with venetoclax/azacitidine, comparing outcomes with a cli
Autor:
Stephan Stilgenbauer, Lang Zhou, Su Young Kim, Shuo Ma, Michael Hallek, Kathryn Humphrey, Barbara Eichhorst, Brenda Chyla, Andrew W. Roberts, John C. Byrd, Steven Coutre, John F. Seymour, Thomas J. Kipps, Jalaja Potluri, Matthew S. Davids, William G. Wierda, Maria Verdugo, Jacqueline Nielsen
Publikováno v:
Blood. 134:111-122
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) enro
Autor:
Jacqueline C. Barrientos, Susan O'Brien, Ulrich Jaeger, Nishitha Reddy, Jennifer R. Brown, Steven Coutre, Constantine S. Tam, Peter Hillmen, Danelle F. James, John C. Byrd, Richard R. Furman, John M. Pagel, Patrick Thornton, Remus Vezan, Paul M. Barr, Jan A. Burger, Sandra Dai, Jennifer A. Woyach, Carol Moreno, Thomas J. Kipps, Stephen P. Mulligan, Marco Montillo
Publikováno v:
Blood
BLOOD
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
BLOOD
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase 3 RESONATE trial, which compared single-agent ibrutinib to ofatumumab in high-risk, relaps